Business
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities
Regen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities.
About this update from Regen Biopharma, Inc.
[{"type":"text","content":"\n\n\n\nRegen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities\n\n\n\n\n\nRegen BioPharma, Inc. Updates Shareholders on Status of Non-Dilutive Funding Opportunities\nCo-development and partnership relationships are major focus of funding arrangements\nPR Newswire\nSAN DIEGO, California, August 25, 2016\n\n\n\nSAN DIEGO, California, August 25, 2016 /PRNewswire/ --\n\nRegen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), is pleased to announce that significant interest is being expressed by potential strategic partners with regards to the Company's proprietary assets. Previously, the Company had announced that partnering strategies were to be explored with the goal to provide sources of non-dilutive funding. Objective Capital Partners, LLC is serving as exclusive advisor to the Company and assisting in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide sources of non-dilutive funding.  \n\n     (Logo: http://photos.prnewswire.com/prnh/20160229/338345 )\n\n\n\"We are pleased with the progress being made by our advisor to identify potential partnerships that can support the growth needs of our several therapeutic assets including HemaXellerate, our most advanced asset for aplastic anemia and chemotherapy-induced myelosuppression, and our novel NR2F6 programs for immune oncology and autoimmune disorders,\" said David Koos, Ph.D., Regen's Chief Executive Officer.  \"Over the past year, there have been numerous partnering transactions that have occurred between large pharmaceutical companies and smaller biotechnology companies like Regen which demonstrate an appetite for investment in early stage companies with novel technologies which address significant markets. While we cannot guarantee success in signing a licensing arrangement, we believe our assets will be able to attract the sort of best in class partners which will maximize the Company's success and that strategic partnerships will play a major role in the further development of our assets.\"  \n\nRegen BioPharma's pipeline includes autologous cell therapies (HemaXellerate, dCellVax, tCellVax), universal donor cell therapy (ucVax) and small molecules (NR2F6 program). HemaXellerate is the subject of an Investigational New Drug Application (IND) an...